Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | EDNRA | P25101 | 14/20 | 0.62 |
| ▸ | CCR4 | P51679 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7395016 | 0.93 | ABCB11 (0.72) | ABCB11EDNRACCR4 | |
| SCHEMBL7395488 | 0.91 | ABCB11 (0.69) | ABCB11EDNRACCR4 | |
| SCHEMBL7363876 | 0.90 | ABCB11 (0.75) | ABCB11EDNRACCR4 | |
| SCHEMBL795587 | 0.90 | ABCB11 (0.78) | ABCB11EDNRACCR4 | |
| SCHEMBL7391495 | 0.89 | ABCB11 (0.71) | ABCB11EDNRACCR4 | |
| SCHEMBL7365954 | 0.88 | ABCB11 (0.66) | ABCB11EDNRACCR4 | |
| SCHEMBL7949490 | 0.88 | EDNRA (0.58) | ABCB11EDNRACCR4 | |
| SCHEMBL7365882 | 0.87 | ABCB11 (0.76) | ABCB11EDNRACCR4 | |
| SCHEMBL7358242 | 0.86 | ABCB11 (0.81) | ABCB11EDNRACCR4 | |
| SCHEMBL7357895 | 0.85 | ABCB11 (0.79) | ABCB11EDNRACCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | claimed |
| US-20260021078-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PULMONARY HYPERTENSION | VIVUS LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20260021051-A1 | PHARMACEUTICAL FORMULATIONS | VIVUS LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3643309-B1 | NINTEDANIB FOR USE IN THE TREATMENT OF SYSTEMIC SCLERODERMA | BOEHRINGER INGELHEIM INT (DE) | 2025-12-03 | — | — | EP | disclosed |
| EP-4573371-A2 | DIAGNOSIS AND TREATMENT OF ACUTE KIDNEY INJURY | The Johns Hopkins University (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240238259-A1 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION | AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER | 2024-07-18 | — | — | US | disclosed |
| WO-2024040225-A9 | DIAGNOSIS AND TREATMENT OF ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024040225-A2 | DIAGNOSIS AND TREATMENT OF ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| EP-3244968-B1 | COMBINATION THERAPY FOR PULMONARY HYPERTENSION | VIVUS LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-20020098186-A1 | Use of endothelin inhibitors for treatment or prevention of fibrotic disorders | SCHUPPAN DETLEF (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6060475-A | Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof | ZENECA LIMITED (GB) | 2000-05-09 | — | — | US | disclosed |
| US-5866568-A | ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY | ZENECA LIMITED (GB) | 1999-02-02 | — | — | US | disclosed |
| EP-0832082-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040681-A1 | N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ZENECA LIMITED (GB) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113396-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | ABCB11 1439/4885EDNRA 6/4885CCR4 1080/4885 |
| US-20260021051-A1 | PHARMACEUTICAL FORMULATIONS | BMPR2, BMP2, ACVR2A | ABCB11 1672/4885EDNRA 173/4885CCR4 3938/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | ABCB11 2091/4885EDNRA 11/4885CCR4 2529/4885 |
| US-20260021078-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF PULMONARY HYPERTENSION | BMPR2, BMPR1B, BMP2 | ABCB11 917/4885EDNRA 82/4885CCR4 1922/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | ABCB11 277/4885EDNRA 41/4885CCR4 2941/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ABCB11 2551/4885EDNRA 2/4885CCR4 1000/4885 |
| US-20020098186-A1 | Use of endothelin inhibitors for treatment or prevention of fibrotic disorders | EDNRB, EDNRA, ECE1 | ABCB11 2777/4885EDNRA 2/4885CCR4 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.